Tessera
Folgen

Joris van de Haar, MD, PhD

@joris-vd-haar.bsky.social

Clinician-scientist / precision medicine / cancer immunology / bioinformatics / MD, PhD @Netherlands Cancer Institute / ESMO precision medicine working group Trying to have fun discovering stuff to help patients. Opinions are my own.

147 Posts3676 Follower1425 Folgt
Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · 6mo ago

Postdoc alert in spatial biology! Building upon our previous work with MSI cancers (e.g. de Vries et al, Nature, 2023), the Voest Group at the NKI is hiring a (fully funded) postdoctoral fellow with strong expertise in spatial cancer biology. Learn more / apply here: www.nki.nl/careers-stud...

Computational Postdoc | Netherlands Cancer Institute

Computational Postdoc Voest Lab (fully funded) — Spatial Decoding of Unconventional Antitumor Immunity in Colorectal Cancer

nki.nl

Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · 9mo ago

🚀 We’re hiring! Join our team at the NKI as a Postdoc, using Quantitative Membrane Proteomics to design novel cancer immunotherapies! Best of two worlds from the Voest and Lindeboom Labs. Cutting-edge proteomics, translational immunotherapy and world-class instrumentation? let’s connect! 🔬💡

Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · last yr.

Very cool study! A very logical explanation for the fundamental question how non-stem cells “know” they need to become one after tissue damage. And is this deregulated in cancer?

Snippert lab@hugosnippert.bsky.social · last yr.

📢 New preprint 🔥 1/ Stem cell regeneration is often viewed as an actively induced process, triggered by damage. But what if plasticity is actively suppressed by the stem cells themselves? We explored plasticity with 'new' cell type ablation tech in normal human colon organoids tinyurl.com/3ky4ccxf

Danielle Bianchi@daaninthelab.bsky.social · last yr.

In today’s publication in Science we introduce Zincore: a novel protein of QRICH1 and SEPHS1 and functions as a transcriptional coregulator dedicated to zinc finger transcription factors. Here’s how we found it: 🧵 www.science.org/doi/10.1126/... 1/11

Zincore, an atypical coregulator, binds zinc finger transcription factors to control gene expression

Zinc finger proteins (ZNFs) are the largest family of transcription factors, yet how they activate gene expression remains unclear. In this study, we identified Zincore, a protein complex consisting o...

science.org

Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · 2y ago

Magnificent work from Monika Wolkers and team : γδ T cells are the prime anti-tumoral T cells in pediatric neuroblastoma Another case where γδ T cells are the central effectors of anticancer immunity. www.biorxiv.org/content/10.1... @forum-gd.bsky.social

γδ T cells are the prime anti-tumoral T cells in pediatric neuroblastoma

High-risk pediatric neuroblastoma patients have a dismal survival rate despite intensive treatment regimens. New treatment options are thus required. Even though HLA expression in neuroblastoma is low and immune cell infiltrates are limited, the presence of tumor infiltrating lymphocytes (TILs) is indicative for better patient survival. Here, we show that most tumor lesions contain viable immune cell infiltrates after induction chemotherapy, with high percentages of CD3+ T cells. We therefore expanded the TILs and tested their anti-tumoral activity. With sufficient starting material, TIL expansion was as efficient as for adult solid tumors. However, whereas TIL products from adult tumors almost exclusively contained αβ T cells, in neuroblastoma-derived TILs, γδ T cells expanded with similar efficacy as αβ T cells. Importantly, the anti-tumor responses in response to autologous tumor digest primarily originated from (Vδ1- and Vδ3-expressing) γδ T cells, and not from αβ T cells. In conclusion, this finding creates a window of opportunity for immunotherapy for neuroblastoma patients, with γδ T cells as potential prime responders. ### Competing Interest Statement The authors have declared no competing interest.

biorxiv.org

Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · 2y ago

Big if true: do cancer cells transfer mutated mitochondria into tumor infiltrating lymphocytes to impair their function? mtDNA is challenging to work with, so looking forward to see this finding confirmed. But cool concept and big congrats to the authors! www.nature.com/articles/s41...

Immune evasion through mitochondrial transfer in the tumour microenvironment - Nature

Mitochondria with mutations in their DNA from cancer cells can be transferred to T cells in the tumour microenvironment, which leads to T cell dysfunction and impaired antitumour immunity.

nature.com

Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · 2y ago

Bizarre story. Genetic Analysis of a Sarcoma Accidentally Transplanted from a Patient to a Surgeon | New England Journal of Medicine www.nejm.org/doi/full/10....

Genetic Analysis of a Sarcoma Accidentally Transplanted from a Patient to a Surgeon | NEJM

Modern concepts of cancer immunology originated from the classic observations by Jensen, Loeb, Tyzzer, and Little in the early years of the 20th century of the rejection of transplanted allogeneic ...

nejm.org

Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · 2y ago

Looking forward to speaking at the Clinical Cancer Genomics conference on March 20-21, 2025 in Amsterdam. Very nice and inspiring program with many European heavyweights, inc Edwin & many others. Register via the link below!👇

Edwin Cuppen@ecuppen.bsky.social · 2y ago

I'm pleased to share that I will be speaking at the Clinical Cancer Genomics meeting, taking place on the 20th-21st of March 2025 in Amsterdam. Register now to join me and discuss the latest developments with leading experts in the field: www.ccg2025.eu #CCG2025

Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · 2y ago

Some cool novel concepts: Nat biotech: platelets for targeted degrader delivery www.nature.com/articles/s41... Science: T cells for targeted drug delivery www.science.org/doi/10.1126/... www.science.org/doi/10.1126/... www.science.org/doi/10.1126/...

Engineered platelets as targeted protein degraders and application to breast cancer models - Nature Biotechnology

Protein degradation is targeted to disease sites using engineered platelets.

nature.com

Joris van de Haar, MD, PhD@joris-vd-haar.bsky.social · 2y ago

Beautiful study by Jacco van Rheenen, Colinda Scheele & team about the impact of the menstrual cycle on neoadjuvant chemotherapy in young women with breast cancer. Cutting-edge fundamental science with direct implications for women and families @nkinl.bsky.social www.nature.com/articles/s41...

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy - Nature

In three mouse models of breast cancer, we show reduced responses to neoadjuvant chemotherapy when treatment is initiated during the dioestrus stage, when compared with initiation during the oestrus s...

nature.com